Baseline Characteristics Module
The Baseline Characteristics Module provides demographic and baseline characteristics information for participants in a clinical trial. This module includes data such as population descriptions and the types of units analyzed, helping researchers understand the baseline characteristics of study participants.
Baseline Characteristics Module path is as follows:
Study -> Results Section -> Baseline Characteristics Module
Baseline Characteristics Module
Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2025-12-26 @ 3:18 AM
NCT ID:
NCT02705820
Population Description:
Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to immune related Response Criteria (irRC) or lack of tolerability, or until the patient declines further treatment for patients that have not progressed to first line chemotherapy for advanced / metastatic NSCLC.
Study:
NCT02705820
Study Brief:
Results Section:
NCT02705820